Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Acetylation of muscle creatine kinase negatively impacts high-energy phosphotransfer in heart failure
Matthew A. Walker, Juan Chavez, Outi Villet, Xiaoting Tang, Andrew Keller, James E. Bruce, Rong Tian
Matthew A. Walker, Juan Chavez, Outi Villet, Xiaoting Tang, Andrew Keller, James E. Bruce, Rong Tian
View: Text | PDF
Research Article Cardiology

Acetylation of muscle creatine kinase negatively impacts high-energy phosphotransfer in heart failure

  • Text
  • PDF
Abstract

A hallmark of impaired myocardial energetics in failing hearts is the downregulation of the creatine kinase (CK) system. In heart failure patients and animal models, myocardial phosphocreatine content and the flux of the CK reaction are negatively correlated with the outcome of heart failure. While decreased CK activity is highly reproducible in failing hearts, the underlying mechanisms remains elusive. Here, we report an inverse relationship between the activity and acetylation of CK muscle form (CKM) in human and mouse failing hearts. Hyperacetylation of recombinant CKM disrupted MM homodimer formation and reduced enzymatic activity, which could be reversed by sirtuin 2 treatment. Mass spectrometry analysis identified multiple lysine residues on the MM dimer interface, which were hyperacetylated in the failing hearts. Molecular modeling of CK MM homodimer suggested that hyperacetylation prevented dimer formation through interfering salt bridges within and between the 2 monomers. Deacetylation by sirtuin 2 reduced acetylation of the critical lysine residues, improved dimer formation, and restored CKM activity from failing heart tissue. These findings reveal a potentially novel mechanism in the regulation of CK activity and provide a potential target for improving high-energy phosphoryl transfer in heart failure.

Authors

Matthew A. Walker, Juan Chavez, Outi Villet, Xiaoting Tang, Andrew Keller, James E. Bruce, Rong Tian

×

Figure 6

Acetylation reduced CKM activity by preventing dimer formation in the failing heart.

Options: View larger image (or click on image) Download as PowerPoint
Acetylation reduced CKM activity by preventing dimer formation in the fa...
(A) Cardiac lysates from sham and TAC-stressed hearts were run on native-PAGE. Representative immunoblot (left) of dimeric versus monomeric CKM. Statistical analysis (right); n = 5 each group. (B and C) Enriched CKM from TAC-stressed hearts was incubated with ± Sirt2 for an in vitro deacetylation reactions prior to native-PAGE to determine dimeric versus monomeric CKM (B) or aliquots were used to determine specific activity of CKM (C). (D) Acetylation sites of failing heart CKM compared with reversible in vitro acetylation sites on human recombinant CKM. Venn diagrams showing hyperacetylated lysine residues identified in failing hearts that also participate in salt bridge formations and were sensitive to deacetylation by Sirt2. Data shown as mean ± SEM; n = 5 per group. P value calculated by 1-way ANOVA followed by Tukey post hoc analysis. *P < 0.05 versus sham dimer, #P < 0.05 versus sham monomer (A and B) or *P < 0.05 versus sham, #P < 0.05 versus TAC (C).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts